Answers are grounded in this paper and cite their sources.
The cGAS-STING signaling pathway serves as a crucial sentinel in innate immunity, detecting cytosolic DNA to initiate robust type I interferon and inflammatory responses. Its precise regulation is vital for host defense, autoimmunity, and cancer immunosurveillance. Emerging evidence highlights that post-transcriptional epigenetic mechanisms, particularly N6-methyladenosine (m 6 A) RNA modification, play a pivotal role in finely tuning this pathway. This review comprehensively summarizes the current understanding of how m 6 A modification governs the cGAS-STING axis at multiple molecular levels. We detail how m 6 A methyltransferases (“writers”), binding proteins (“readers”), and demethylases (“erasers”) directly or indirectly regulate the stability, translation, and degradation of the core components of this pathway, with direct evidence established for cGAS and STING transcripts, as well as indirect regulation of downstream signalling effectors including TBK1 and IRF3 through m 6 A-dependent modulation of upstream regulators and signaling cascades. Furthermore, we discuss the dysregulation of m 6 A-mediated epigenetic control of cGAS-STING in the pathogenesis of various diseases, including autoimmune disorders, chronic inflammatory conditions, infectious diseases, and cancers. The dual role of this regulatory layer-both promoting and suppressing disease progression depending on the cellular context-is critically examined. Finally, we explore the therapeutic potential of targeting m 6 A modifiers to modulate the cGAS-STING pathway, proposing future research directions to harness this epigenetic mechanism for novel diagnostic and therapeutic strategies across a spectrum of diseases.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: